XML 25 R17.htm IDEA: XBRL DOCUMENT
v3.23.3

Goodwill and other intangible assets | 9 Months Ended
--- | ---
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and other intangible assets | Goodwill and other intangible assets Goodwill The change in the carrying amount of goodwill was as follows (in millions):
| Nine months ended September 30, 2023
Beginning balance | $ | 15,529 |
Adjustments to goodwill resulting from acquisitions and divestitures, net | (22) |
Currency translation adjustment | 2 |
Ending balance | $ | 15,509 |
Other intangible assets Other intangible assets consisted of the following (in millions):
| September 30, 2023 |  | December 31, 2022
| Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net |  | Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net
Finite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |
Developed-product-technology rights | $ | 29,028 |  |  | $ | (16,931) |  |  | $ | 12,097 |  |  | $ | 29,028 |  |  | $ | (15,045) |  |  | $ | 13,983 |
Licensing rights | 3,864 |  |  | (3,233) |  |  | 631 |  |  | 3,864 |  |  | (3,123) |  |  | 741 |
Marketing-related rights | 1,339 |  |  | (1,243) |  |  | 96 |  |  | 1,326 |  |  | (1,167) |  |  | 159 |
Research and development technology rights | 1,377 |  |  | (1,209) |  |  | 168 |  |  | 1,378 |  |  | (1,190) |  |  | 188 |
Total finite-lived intangible assets | 35,608 |  |  | (22,616) |  |  | 12,992 |  |  | 35,596 |  |  | (20,525) |  |  | 15,071 |
Indefinite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |
In-process research and development | 158 |  |  | — |  |  | 158 |  |  | 1,009 |  |  | — |  |  | 1,009 |
Total other intangible assets | $ | 35,766 |  |  | $ | (22,616) |  |  | $ | 13,150 |  |  | $ | 36,605 |  |  | $ | (20,525) |  |  | $ | 16,080 |
Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses. IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the three months ended September 30, 2023, the development of AMG 340 acquired in connection with our Teneobio acquisition was terminated, resulting in an impairment charge of $783 million, which was recognized in Other operating expenses in the Condensed Consolidated Statements of Income and included in Other items, net, in the Condensed Consolidated Statements of Cash Flows. See Note 12, Fair value measurement, for the impact on the related contingent consideration liability. During the three months ended September 30, 2023 and 2022, we recognized amortization associated with our finite-lived intangible assets of $693 million and $628 million, respectively. During the nine months ended September 30, 2023 and 2022, we recognized amortization associated with our finite-lived intangible assets of $2.1 billion and $1.9 billion, respectively. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. As of September 30, 2023, the total estimated amortization of our finite-lived intangible assets for the remaining three months ending December 31, 2023, and the years ending December 31, 2024, 2025, 2026, 2027 and 2028, are $0.7 billion, $2.7 billion, $2.5 billion, $2.1 billion, $2.1 billion and $1.1 billion, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration